Healthcare of Ontario Pension Plan Trust Fund Has $6.55 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Healthcare of Ontario Pension Plan Trust Fund decreased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 20.1% in the first quarter, HoldingsChannel reports. The firm owned 238,000 shares of the company’s stock after selling 60,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Intellia Therapeutics were worth $6,547,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. ARK Investment Management LLC raised its stake in shares of Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after purchasing an additional 1,463,820 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares in the last quarter. Norges Bank purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $16,348,000. Vestmark Advisory Solutions Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $8,110,000. Finally, Pinnacle Associates Ltd. purchased a new stake in shares of Intellia Therapeutics during the 1st quarter worth about $7,035,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 3.2 %

Shares of Intellia Therapeutics stock traded up $0.83 during trading on Thursday, reaching $26.43. 1,604,103 shares of the company were exchanged, compared to its average volume of 1,575,975. Intellia Therapeutics, Inc. has a twelve month low of $19.37 and a twelve month high of $43.06. The business has a 50-day moving average price of $24.28 and a 200-day moving average price of $25.52. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -4.94 and a beta of 1.82.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The company had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -4.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. Truist Financial reissued a “buy” rating and set a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. BMO Capital Markets lifted their price objective on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Finally, StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $69.00.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.